---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000062"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:19:14.996677+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports Q1 net loss of $15.1M; fasedienol Phase 3 data expected Q4 2025 and H1 2026

## Summary
- Net loss $15.1M for fiscal Q1 ended June 30, 2025, vs $10.7M a year ago; R&D expense up to $11.7M.
- Cash, cash equivalents, and marketable securities at $63.2M as of June 30, 2025.
- Topline data from PALISADE-3 Phase 3 trial of fasedienol (SAD) expected Q4 2025; PALISADE-4 data H1 2026.
- PH80 for menopausal hot flashes – IND preparation underway for further Phase 2 development.
- Appointed Elissa Cote as Chief Corporate Development Officer in June 2025.

## SEC filing metadata
- accession: 0001411685-25-000062
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/0001411685-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/vtgn-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000062
- JSON: https://secwatch.observer/filing/0001411685-25-000062.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.